Edition:
United Kingdom

People: Carmat SA (ALCAR.PA)

ALCAR.PA on Paris Stock Exchange

19.96EUR
18 Jun 2019
Change (% chg)

€-0.02 (-0.10%)
Prev Close
€19.98
Open
€19.98
Day's High
€19.98
Day's Low
€19.96
Volume
369
Avg. Vol
4,690
52-wk High
€29.50
52-wk Low
€19.60

Garnier, Jean-Pierre 

Dr. Jean-Pierre Garnier has been appointed as Chairman of the Board at Carmat SA as of December 3, 2018. Scientist and business leader, Mr. Garnier graduated from Universite Louis Pasteur (PhD in Pharmacology) and Stanford University (Master in Business Administration). He started his career in 1975 at the pharmaceutical company Schering-Plough where he held a number of management positions in Europe before becoming President of their American division. In 1990, he joined Smithkline Beecham Laboratories as President of the Pharmaceuticals Division and became President and CEO in 1999. In 2000, he achieved the merge of two of the largest pharmaceutical groups (Smithkline Beecham and Glaxo Wellcome), to create GlaxoSmithKline (GSK), which he chaired until 2008. He is currently a member of the Board of Directors of several biotechnology companies; President of Idorsia, Director of Radius Health. He is also a member of the Board of United Technology (Aeronautics) and a Director of the Paul Newman Foundation. From 2011, Mr. Garnier was Chairman of Actelion (Biotechnology) until its acquisition by Johnson and Johnson in 2017. The Best Practice Institute has nominated Jean-Pierre Garnier as one of the world's top 20 CEOs. He is an Officier de la Legion d’Honneur (Officer of the Legion of Honour) and Knight Commander of the Order of the British Empire.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --